Cargando…

Stable Susceptibility to Aminoglycosides in an Age of Low Level, Institutional Use

INTRODUCTION: The use of aminoglycosides has decreased dramatically over several decades in the United States due to the introduction of safer Gram-negative agents. This study was conducted to assess possibly changing aminoglycoside susceptibility rates between 2006 and 2012 and in reference to 1992...

Descripción completa

Detalles Bibliográficos
Autores principales: Bosso, John A., Haines, Martha L., Gomez, Juanmanuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108105/
https://www.ncbi.nlm.nih.gov/pubmed/25134483
http://dx.doi.org/10.1007/s40121-013-0016-4
_version_ 1782327709727195136
author Bosso, John A.
Haines, Martha L.
Gomez, Juanmanuel
author_facet Bosso, John A.
Haines, Martha L.
Gomez, Juanmanuel
author_sort Bosso, John A.
collection PubMed
description INTRODUCTION: The use of aminoglycosides has decreased dramatically over several decades in the United States due to the introduction of safer Gram-negative agents. This study was conducted to assess possibly changing aminoglycoside susceptibility rates between 2006 and 2012 and in reference to 1992 use in the context of aminoglycoside use volume. METHODS: Quarterly adult use of amikacin, gentamicin and tobramycin were determined from the Medical University of South Carolina Medical Center, Charleston, South Carolina, USA, pharmacy drug use database and expressed as total aminoglycoside defined daily doses per 1,000 patient days for the years 1992 and 2006 through 2012. Annual susceptibility of Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae, for the years 1992, 2006, and 2008 through 2012 were retrieved from our hospital’s clinical microbiology database (duplicate isolates were excluded). Quarterly and annualized aminoglycoside usage rates were compared to the other years of interest. Likewise, susceptibility rates of the target organisms to each aminoglycoside were also compared across the same timeframe. RESULTS: While total use of aminoglycosides decreased slightly from 1992 to 2006, it increased by about 40% between 2006 and 2008 and then stabilized. Changes in susceptibility rates between 1992 and 2006 were all ≤±9% with the exception of K. pneumoniae susceptibility to amikacin (−17%). Changes in susceptibility from 1992 to 2012 were also all ≤±9%. Tobramycin remained the most active versus P. aeruginosa (% susceptible = 90), while amikacin remained most active versus E. coli and K. pneumoniae (% susceptible = 98 and 98, respectively). CONCLUSION: With low level use of aminoglycosides in our institution over the past 2 decades, the susceptibility of key Gram-negative pathogens has remained relatively stable, preserving these agents as potential alternative therapies as resistance arises to other frequently used antibiotics.
format Online
Article
Text
id pubmed-4108105
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-41081052014-07-24 Stable Susceptibility to Aminoglycosides in an Age of Low Level, Institutional Use Bosso, John A. Haines, Martha L. Gomez, Juanmanuel Infect Dis Ther Original Research INTRODUCTION: The use of aminoglycosides has decreased dramatically over several decades in the United States due to the introduction of safer Gram-negative agents. This study was conducted to assess possibly changing aminoglycoside susceptibility rates between 2006 and 2012 and in reference to 1992 use in the context of aminoglycoside use volume. METHODS: Quarterly adult use of amikacin, gentamicin and tobramycin were determined from the Medical University of South Carolina Medical Center, Charleston, South Carolina, USA, pharmacy drug use database and expressed as total aminoglycoside defined daily doses per 1,000 patient days for the years 1992 and 2006 through 2012. Annual susceptibility of Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae, for the years 1992, 2006, and 2008 through 2012 were retrieved from our hospital’s clinical microbiology database (duplicate isolates were excluded). Quarterly and annualized aminoglycoside usage rates were compared to the other years of interest. Likewise, susceptibility rates of the target organisms to each aminoglycoside were also compared across the same timeframe. RESULTS: While total use of aminoglycosides decreased slightly from 1992 to 2006, it increased by about 40% between 2006 and 2008 and then stabilized. Changes in susceptibility rates between 1992 and 2006 were all ≤±9% with the exception of K. pneumoniae susceptibility to amikacin (−17%). Changes in susceptibility from 1992 to 2012 were also all ≤±9%. Tobramycin remained the most active versus P. aeruginosa (% susceptible = 90), while amikacin remained most active versus E. coli and K. pneumoniae (% susceptible = 98 and 98, respectively). CONCLUSION: With low level use of aminoglycosides in our institution over the past 2 decades, the susceptibility of key Gram-negative pathogens has remained relatively stable, preserving these agents as potential alternative therapies as resistance arises to other frequently used antibiotics. Springer Healthcare 2013-10-22 2013-12 /pmc/articles/PMC4108105/ /pubmed/25134483 http://dx.doi.org/10.1007/s40121-013-0016-4 Text en © The Author(s) 2013 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Research
Bosso, John A.
Haines, Martha L.
Gomez, Juanmanuel
Stable Susceptibility to Aminoglycosides in an Age of Low Level, Institutional Use
title Stable Susceptibility to Aminoglycosides in an Age of Low Level, Institutional Use
title_full Stable Susceptibility to Aminoglycosides in an Age of Low Level, Institutional Use
title_fullStr Stable Susceptibility to Aminoglycosides in an Age of Low Level, Institutional Use
title_full_unstemmed Stable Susceptibility to Aminoglycosides in an Age of Low Level, Institutional Use
title_short Stable Susceptibility to Aminoglycosides in an Age of Low Level, Institutional Use
title_sort stable susceptibility to aminoglycosides in an age of low level, institutional use
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108105/
https://www.ncbi.nlm.nih.gov/pubmed/25134483
http://dx.doi.org/10.1007/s40121-013-0016-4
work_keys_str_mv AT bossojohna stablesusceptibilitytoaminoglycosidesinanageoflowlevelinstitutionaluse
AT hainesmarthal stablesusceptibilitytoaminoglycosidesinanageoflowlevelinstitutionaluse
AT gomezjuanmanuel stablesusceptibilitytoaminoglycosidesinanageoflowlevelinstitutionaluse